DE19534745A1 - Verfahren zur Herstellung von 3-[4-(2-Aminoethoxy)benzoyl]-2-aryl-6-hydroxybenzo[b]thiophenen - Google Patents
Verfahren zur Herstellung von 3-[4-(2-Aminoethoxy)benzoyl]-2-aryl-6-hydroxybenzo[b]thiophenenInfo
- Publication number
- DE19534745A1 DE19534745A1 DE19534745A DE19534745A DE19534745A1 DE 19534745 A1 DE19534745 A1 DE 19534745A1 DE 19534745 A DE19534745 A DE 19534745A DE 19534745 A DE19534745 A DE 19534745A DE 19534745 A1 DE19534745 A1 DE 19534745A1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxy
- chlorine
- compound
- formula
- benzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Description
(a) Acylierung eines Benzothiophens der Formel II
mit einem Acylierungsmittel der Formel III
worin X′ Chlor oder Brom ist,
(b) Dealkylierung einer oder mehrerer phenolischer Grup pen durch Umsetzung mit weiterem BX′₃, worin X′ wie oben defi niert ist, und
(c) Isolierung des kristallinen Solvats.
(a) Acylierung eines Benzothiophens der Formel II
in Gegenwart von BX′₃, worin X′ Chlor oder Brom ist,
(b) Dealkylierung der phenolischen Gruppen des Acylie rungsprodukts der Stufe (a) durch Umsetzung mit weiterem Bx₃′, worin XX wie oben definiert ist,
(c) Isolierung eines kristallinen Solvats einer Verbin dung der Formel I
(d) Umsetzung dieses kristallinen Solvats in Methanol oder in einem Gemisch aus Methanol und Wasser mit etwa 1 Äquiva lent einer Base,
(e) gegebenenfalls Extraktion der Lösung der Stufe (d) mit einem aliphatischen Kohlenwasserstofflösemittel,
(f) Zugabe von etwa 1 Äquivalent Chlorwasserstoffsäure zur methanolischen Lösung der Stufe (d) oder (e) und
(g) Isolierung der nicht solvatisierten kristallinen Ver bindung.
(a) Acylierung eines Benzothiophens der Formel II
in Gegenwart von BX′₃, worin X′ Chlor oder Brom ist,
(b) Dealkylierung der phenolischen Gruppen des Acylie rungsprodukts der Stufe (a) durch Umsetzung mit weiterem BX′₃, worin X¹ wie oben definiert ist,
(c) Isolierung eines kristallinen Solvats einer Verbin dung der Formel I
(d) Auflösung dieses kristallinen Solvats in einer Metha nol und Wasser enthaltenden heißen Lösung,
(e) gegebenenfalls Filtration der Lösung der Stufe (d),
(f) Konzentration der Lösung der Stufe (d) oder (e) durch Destillation und
(g) Isolierung der nicht solvatisierten kristallinen Ver bindung.
D = Mittleres Verhältnis des Standards für das besondere Lösemittel
E = Mittleres Gewicht des Standards
F = Gewicht der Probe (mg)
G = Volumen der Probe (10 ml)
H = Volumen des Standards (10 000 ml)
I = Reinheit des Standards (%)
Claims (12)
- (a) Acylierung eines Benzothiophens der Formel II worin R⁴ Wasserstoff oder G₁-C₄-Alkoxy ist und R⁵ für G₁-G₄-Alkyl steht, mit einem Acylierungsmittel der Formel III worin R⁶ Chlor, Brom oder Hydroxy ist und HX, R² und R³ wie oben definiert sind, in Gegenwart von BX′₃, worin X′ Chlor oder Brom ist,
- (b) Dealkylierung einer oder mehrerer phenolischer Grup pen durch Umsetzung mit weiterem BX′3, worin X′ wie oben defi niert ist, und
- (c) Isolierung des kristallinen Solvats.
- (a) Dealkylierung einer oder mehrerer phenolischer Grup pen einer Verbindung der Formel IV worin R⁴ Wasserstoff oder C₁-C₄-Alkoxy ist, R⁵ für C₁-C₄-Alkyl steht und HX, R² und R³ wie oben definiert sind, durch Umsetzung mit BX′₃, worin X′ Chlor oder Brom ist, und
- (b) Isolierung des kristallinen Solvats.
- (a) Acylierung eines Benzothiophens der Formel II worin R⁴ Wasserstoff oder C₁-C₄-Alkoxy ist und R⁵ für C₁-C₄-Alkyl steht, mit einem Acylierungsmittel der Formel III worin R⁶ Chlor, Brom oder Hydroxy ist, R² und R³ zusammen mit dem benachbarten Stickstoffatom eine Pyridinogruppe bilden, HX für HCl oder HBr steht und in Gegenwart von BX′₃, worin X′ Chlor oder Brom ist,
- (b) Dealkylierung der phenolischen Gruppen des Acylie rungsprodukts der Stufe (a) durch Umsetzung mit weiterem BX′₃, worin X′ wie oben definiert ist, und
- (c) Isolierung eines kristallinen Solvats einer Verbin dung der Formel I worin R¹ für Hydroxy steht und HX, R² und R³ wie oben definiert sind,
- (d) Umsetzung dieses kristallinen Solvats in Methanol oder in einem Gemisch aus Methanol und Wasser mit etwa 1 Äquiva lent einer Base,
- (e) gegebenenfalls Extraktion der Lösung der Stufe (d) mit einem aliphatischen Kohlenwasserstofflösemittel,
- (f) Zugabe von etwa 1 Äquivalent Chlorwasserstoffsäure zur methanolischen Lösung der Stufe (d) oder (e) und
- (g) Isolierung der nicht solvatisierten kristallinen Ver bindung.
- (a) Acylierung eines Benzothiophens der Formel II worin R⁴ Wasserstoff oder C₁-C₄-Alkoxy ist und R⁵ für C₁-C₄-Alkyl steht, mit einem Acylierungsmittel der Formel III worin R⁶ Chlor, Brom oder Hydroxy ist und R² und R³ zusammen mit dem benachbarten Stickstoffatom eine Piperidinogruppe bilden, HX für HCl oder HBr steht und in Gegenwart von BX′₃, worin X′ Chlor oder Brom ist,
- (b) Dealkylierung der phenolischen Gruppen des Acylie rungsprodukts der Stufe (a) durch Umsetzung mit weiterem BX′₃, worin X′ wie oben definiert ist, und
- (c) Isolierung eines kristallinen Solvats einer Verbin dung der Formel I worin R¹ für Hydroxy steht und HX, R² und R³ wie oben definiert sind,
- (d) Auflösung des kristallinen Solvats in einer Methanol und Wasser enthaltenden heißen Lösung,
- (e) gegebenenfalls Filtration der Lösung von Stufe (d),
- (f) Konzentration der Lösung von Stufe (d) oder (e) durch Destillation und
- (g) Isolierung der nicht solvatisierten kristallinen Ver bindung.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/308,325 US5629425A (en) | 1994-09-19 | 1994-09-19 | Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene |
US308325 | 1994-09-19 | ||
US42791495A | 1995-04-26 | 1995-04-26 | |
US427914 | 1995-04-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE19534745A1 true DE19534745A1 (de) | 1996-04-04 |
DE19534745B4 DE19534745B4 (de) | 2004-06-09 |
Family
ID=26976194
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19534745A Expired - Fee Related DE19534745B4 (de) | 1994-09-19 | 1995-09-19 | Verfahren zur Herstellung von 6-Hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophen |
DE19549755A Expired - Fee Related DE19549755B4 (de) | 1994-09-19 | 1995-09-19 | Verfahren zur Herstellung eines nicht solvatisierten kristallinen Raloxifenhydrochlorids |
DE19534744A Ceased DE19534744A1 (de) | 1994-09-19 | 1995-09-19 | Neues pharmazeutisches Produkt |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19549755A Expired - Fee Related DE19549755B4 (de) | 1994-09-19 | 1995-09-19 | Verfahren zur Herstellung eines nicht solvatisierten kristallinen Raloxifenhydrochlorids |
DE19534744A Ceased DE19534744A1 (de) | 1994-09-19 | 1995-09-19 | Neues pharmazeutisches Produkt |
Country Status (51)
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39049E1 (en) | 1992-07-28 | 2006-03-28 | Eli Lilly And Company | Methods for inhibiting bone loss |
USRE38968E1 (en) | 1992-07-28 | 2006-02-07 | Eli Lilly And Company | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride |
TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
US5478847A (en) | 1994-03-02 | 1995-12-26 | Eli Lilly And Company | Methods of use for inhibiting bone loss and lowering serum cholesterol |
CO4410190A1 (es) * | 1994-09-19 | 1997-01-09 | Lilly Co Eli | 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO |
PT910369E (pt) * | 1996-03-26 | 2010-06-04 | Lilly Co Eli | Benzotiofenos, formulações que os contêm, e métodos |
US6458811B1 (en) * | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
RU2203060C2 (ru) | 1996-10-30 | 2003-04-27 | Эли Лилли Энд Компани | Способ профилактики рака молочной железы |
CA2236254A1 (en) * | 1997-04-30 | 1998-10-30 | David Warren Hoard | Process for preparing benzo¬b|thiophenes |
ATE301129T1 (de) | 1999-05-04 | 2005-08-15 | Strakan Int Ltd | Androgen glykoside und die androgenische aktivität davon |
WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
AU2002230409A1 (en) * | 2000-11-27 | 2002-06-03 | Eli Lilly And Company | Process for preparing 3-aryl-benzo(b)thiophenes |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
EP1826205A1 (de) | 2002-09-30 | 2007-08-29 | A/S GEA Farmaceutisk Fabrik | Neue Bernsteinsäureadditionssalze aus Raloxifen und/oder Solvate daraus sowie pharmazeutische Zusammensetzungen damit |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
US20060106010A1 (en) * | 2003-05-27 | 2006-05-18 | Black Larry J | Methods for inhibiting bone loss |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
DE102004033670A1 (de) | 2004-07-09 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel |
US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
EP1630163A1 (de) | 2004-08-25 | 2006-03-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
SG155996A1 (en) | 2004-09-29 | 2009-10-29 | Bayer Schering Pharma Ag | Thermodynamically stable form of bay 43-9006 tosylate |
US20060068010A1 (en) * | 2004-09-30 | 2006-03-30 | Stephen Turner | Method for improving the bioavailability of orally delivered therapeutics |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
CA2810839A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine |
EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
KR20090082399A (ko) * | 2006-10-17 | 2009-07-30 | 씨아이피엘에이 엘티디. | 벤조티오펜 화합물의 결정형 및 그의 제조방법 |
US20080103295A1 (en) * | 2006-10-25 | 2008-05-01 | David Losan Ho | Process for the preparation of sucrose-6-ester by esterification in the presence of solid superacid catalyst |
US8258291B2 (en) * | 2006-10-25 | 2012-09-04 | Mamtek International Limited | Process for the preparation of sucralose by the chlorination of sugar with triphosgene (BTC) |
DE102007032451B4 (de) | 2007-07-12 | 2010-09-30 | Icfs Gmbh | Verfahren zur Herstellung von aromatischen Ketonen |
US20090023799A1 (en) * | 2007-07-20 | 2009-01-22 | George Laurence | CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE |
CA2695406A1 (en) | 2007-08-03 | 2009-02-12 | Boehringer Ingelheim International Gmbh | Crystalline form of a dihydropteridione derivative |
EP2242483B1 (de) * | 2007-12-21 | 2013-02-20 | Synthon B.V. | Raloxifen-zusammensetzung |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2307399B1 (de) * | 2008-06-09 | 2016-05-18 | ERREGIERRE S.p.A. | Verfahren zur steuerung des raloxifene hydrochlorid kristallwachstums |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
MX2011006713A (es) | 2008-12-23 | 2011-07-13 | Boehringer Ingelheim Int | Formas salinas de compuesto organico. |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
ES2437916T3 (es) | 2009-07-02 | 2014-01-15 | Synthon B.V. | Composición de raloxifeno |
EP2314581B1 (de) | 2009-10-23 | 2012-07-25 | Hexal AG | Verfahren zur Herstellung von Benzo[b]thiophenderivaten |
KR20120107080A (ko) | 2009-11-27 | 2012-09-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
WO2011099942A1 (en) | 2010-02-09 | 2011-08-18 | Silverstone Pharma | New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy |
JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
AU2011268940B2 (en) | 2010-06-24 | 2015-05-21 | Boehringer Ingelheim International Gmbh | Diabetes therapy |
US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
IT1403083B1 (it) * | 2010-10-25 | 2013-10-04 | Fidia Farmaceutici | Nuova forma polimorfa di raloxifene cloridrato |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
NZ618698A (en) | 2011-07-15 | 2015-08-28 | Boehringer Ingelheim Int | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014135834A1 (en) | 2013-03-05 | 2014-09-12 | Cipla House | Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator |
EP3024464A1 (de) | 2013-07-26 | 2016-06-01 | Boehringer Ingelheim International GmbH | Behandlung des myelodysplastischen syndroms |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
CN104496963A (zh) * | 2014-12-02 | 2015-04-08 | 千辉药业(安徽)有限责任公司 | 一种盐酸雷洛昔芬的制备方法 |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3869485A (en) * | 1969-09-25 | 1975-03-04 | Allied Chem | Preparation of acid chlorides with phosgene in the presence of a catalyst |
GB1456323A (en) * | 1974-06-06 | 1976-11-24 | Labaz | Benzothiophenes process for preparing them and pharmaceutical compositions containing the same |
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
ZA822247B (en) | 1981-04-03 | 1983-11-30 | Lilly Co Eli | Benzothiophene compounds and process for preparing them |
IL65404A0 (en) * | 1981-04-03 | 1982-07-30 | Lilly Co Eli | Benzothiophene compounds and process for preparing them |
IL65378A (en) | 1981-04-03 | 1986-02-28 | Lilly Co Eli | Process for preparing 3-(4-aminoethoxybenzoyl)benzo-(b)thiophenes |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4358593A (en) * | 1981-04-03 | 1982-11-09 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
IL65379A0 (en) | 1981-04-03 | 1982-05-31 | Lilly Co Eli | Process for preparing acylated benzothiophenes |
DE4117512A1 (de) | 1991-05-25 | 1992-11-26 | Schering Ag | 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
US5169860A (en) * | 1992-03-13 | 1992-12-08 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
TW383306B (en) * | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
TW275584B (de) | 1993-06-24 | 1996-05-11 | Fli Lilly And Co | |
US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US5523416A (en) | 1994-07-22 | 1996-06-04 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxy-benzoyl) benzo (B)-thiophenes |
CO4410190A1 (es) * | 1994-09-19 | 1997-01-09 | Lilly Co Eli | 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO |
-
1995
- 1995-06-02 CO CO95023869A patent/CO4410190A1/es unknown
- 1995-06-02 CO CO95023870A patent/CO4410191A1/es unknown
- 1995-06-05 TW TW084105613A patent/TW412534B/zh not_active IP Right Cessation
- 1995-06-06 US US08/469,961 patent/US6472531B1/en not_active Expired - Lifetime
- 1995-06-06 US US08/467,485 patent/US5731327A/en not_active Expired - Lifetime
- 1995-06-06 US US08/469,093 patent/US6399778B1/en not_active Expired - Fee Related
- 1995-06-07 PE PE1995270673A patent/PE32796A1/es not_active IP Right Cessation
- 1995-06-07 PE PE1995270674A patent/PE14796A1/es not_active Application Discontinuation
- 1995-09-13 ES ES09501774A patent/ES2109882B1/es not_active Revoked
- 1995-09-13 ES ES009501775A patent/ES2129293B1/es not_active Expired - Fee Related
- 1995-09-14 UA UA95094169A patent/UA42716C2/uk unknown
- 1995-09-14 UA UA95094168A patent/UA44240C2/uk unknown
- 1995-09-14 NL NL1001196A patent/NL1001196C2/nl active Search and Examination
- 1995-09-14 IL IL12528395A patent/IL125283A/en not_active IP Right Cessation
- 1995-09-14 IL IL11531595A patent/IL115315A/xx not_active IP Right Cessation
- 1995-09-14 IL IL11531495A patent/IL115314A/xx not_active IP Right Cessation
- 1995-09-14 NL NL1001194A patent/NL1001194C2/nl active Search and Examination
- 1995-09-15 NZ NZ280028A patent/NZ280028A/en not_active IP Right Cessation
- 1995-09-15 RO RO95-01620A patent/RO115260B1/ro unknown
- 1995-09-15 NZ NZ280027A patent/NZ280027A/en not_active IP Right Cessation
- 1995-09-15 NO NO953657A patent/NO308107B1/no not_active IP Right Cessation
- 1995-09-15 PT PT101770A patent/PT101770B/pt not_active IP Right Cessation
- 1995-09-15 IT IT95MI001936A patent/IT1277602B1/it active IP Right Grant
- 1995-09-15 CA CA002158400A patent/CA2158400C/en not_active Expired - Lifetime
- 1995-09-15 DK DK199501027A patent/DK175903B1/da not_active IP Right Cessation
- 1995-09-15 KR KR1019950030210A patent/KR100381346B1/ko active IP Right Grant
- 1995-09-15 NO NO19953658A patent/NO313996B1/no not_active IP Right Cessation
- 1995-09-15 CZ CZ19952403A patent/CZ290343B6/cs not_active IP Right Cessation
- 1995-09-15 IT IT95MI001935A patent/IT1277601B1/it active IP Right Grant
- 1995-09-15 SE SE9503213A patent/SE520721C2/sv not_active IP Right Cessation
- 1995-09-15 UY UY24040A patent/UY24040A1/es not_active IP Right Cessation
- 1995-09-15 PT PT101771A patent/PT101771B/pt not_active IP Right Cessation
- 1995-09-15 CA CA002158399A patent/CA2158399C/en not_active Expired - Lifetime
- 1995-09-15 RO RO95-01619A patent/RO115259B1/ro unknown
- 1995-09-15 SE SE9503214A patent/SE509265C2/sv not_active IP Right Cessation
- 1995-09-15 CZ CZ19952402A patent/CZ292007B6/cs not_active IP Right Cessation
- 1995-09-15 KR KR1019950030209A patent/KR100367376B1/ko active IP Right Grant
- 1995-09-15 DK DK199501028A patent/DK175897B1/da not_active IP Right Cessation
- 1995-09-17 EG EG76395A patent/EG23763A/xx active
- 1995-09-18 CN CN95118629A patent/CN1075069C/zh not_active Expired - Lifetime
- 1995-09-18 BR BR9504060A patent/BR9504060A/pt not_active IP Right Cessation
- 1995-09-18 CH CH02628/95A patent/CH691478A5/de not_active IP Right Cessation
- 1995-09-18 FI FI954402A patent/FI112226B/fi not_active IP Right Cessation
- 1995-09-18 FR FR9510922A patent/FR2732020B1/fr not_active Expired - Fee Related
- 1995-09-18 GB GB9519028A patent/GB2293382B/en not_active Expired - Fee Related
- 1995-09-18 GB GB9519032A patent/GB2293602B/en not_active Expired - Fee Related
- 1995-09-18 LV LVP-95-285A patent/LV11178B/en unknown
- 1995-09-18 HU HU9502721A patent/HU225417B1/hu not_active IP Right Cessation
- 1995-09-18 LU LU88661A patent/LU88661A1/fr unknown
- 1995-09-18 HR HR950483A patent/HRP950483B1/xx not_active IP Right Cessation
- 1995-09-18 AU AU31731/95A patent/AU692907B2/en not_active Ceased
- 1995-09-18 LU LU88660A patent/LU88660A1/fr unknown
- 1995-09-18 FR FR9510921A patent/FR2724655B1/fr not_active Expired - Fee Related
- 1995-09-18 BR BR9504059A patent/BR9504059A/pt not_active IP Right Cessation
- 1995-09-18 LV LVP-95-284A patent/LV11177B/en unknown
- 1995-09-18 MY MYPI95002762A patent/MY116371A/en unknown
- 1995-09-18 GR GR950100341A patent/GR1002709B/el not_active IP Right Cessation
- 1995-09-18 HR HR950482A patent/HRP950482B1/xx not_active IP Right Cessation
- 1995-09-18 AU AU31730/95A patent/AU691955B2/en not_active Expired
- 1995-09-18 SI SI9500293A patent/SI9500293A/sl not_active IP Right Cessation
- 1995-09-18 CH CH01780/00A patent/CH691594A5/de not_active IP Right Cessation
- 1995-09-18 SI SI9500292A patent/SI9500292A/sl not_active IP Right Cessation
- 1995-09-18 GR GR950100340A patent/GR1002697B/el not_active IP Right Cessation
- 1995-09-18 BE BE9500760A patent/BE1009625A3/fr active
- 1995-09-18 AT AT0154295A patent/AT407988B/de not_active IP Right Cessation
- 1995-09-18 AT AT0154395A patent/AT502957A1/de not_active Application Discontinuation
- 1995-09-18 BE BE9500761A patent/BE1009626A3/fr active
- 1995-09-18 CN CN95118449A patent/CN1068324C/zh not_active Expired - Lifetime
- 1995-09-18 CH CH02629/95A patent/CH691125A5/de not_active IP Right Cessation
- 1995-09-18 HU HU9502723A patent/HU227683B1/hu not_active IP Right Cessation
- 1995-09-18 JP JP7238209A patent/JPH08193081A/ja active Pending
- 1995-09-18 JP JP7238211A patent/JP2860071B2/ja not_active Expired - Lifetime
- 1995-09-18 FI FI954403A patent/FI121424B/fi not_active IP Right Cessation
- 1995-09-19 WO PCT/US1995/011872 patent/WO1996009045A1/en active Application Filing
- 1995-09-19 DE DE19534745A patent/DE19534745B4/de not_active Expired - Fee Related
- 1995-09-19 GE GEAP19953626A patent/GEP19991821B/en unknown
- 1995-09-19 AP APAP/P/1997/000938A patent/AP754A/en active
- 1995-09-19 DE DE19549755A patent/DE19549755B4/de not_active Expired - Fee Related
- 1995-09-19 IE IE950721A patent/IE80883B1/en not_active IP Right Cessation
- 1995-09-19 TR TR95/01136A patent/TR199501136A2/xx unknown
- 1995-09-19 SK SK233-97A patent/SK283502B6/sk not_active IP Right Cessation
- 1995-09-19 EE EE9700055A patent/EE03386B1/xx unknown
- 1995-09-19 PL PL95310518A patent/PL182450B1/pl not_active IP Right Cessation
- 1995-09-19 RS YUP-613/95A patent/RS49578B/sr unknown
- 1995-09-19 AU AU37186/95A patent/AU3718695A/en not_active Abandoned
- 1995-09-19 PL PL95310517A patent/PL187686B1/pl not_active IP Right Cessation
- 1995-09-19 DE DE19534744A patent/DE19534744A1/de not_active Ceased
- 1995-09-19 RS YU61495A patent/RS49513B/sr unknown
- 1995-09-19 IE IE950722A patent/IE950722A1/en not_active IP Right Cessation
-
1997
- 1997-01-09 DK DK199700027A patent/DK175887B1/da not_active IP Right Cessation
- 1997-01-09 DK DK199700028A patent/DK175886B1/da not_active IP Right Cessation
- 1997-02-18 BG BG101242A patent/BG62793B1/bg unknown
- 1997-03-18 IS IS4446A patent/IS1788B/is unknown
- 1997-03-19 OA OA60977A patent/OA10406A/en unknown
-
1998
- 1998-12-23 HK HK98115201A patent/HK1019009A1/xx not_active IP Right Cessation
-
2002
- 2002-02-26 US US10/083,179 patent/US20020173645A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE19534745A1 (de) | Verfahren zur Herstellung von 3-[4-(2-Aminoethoxy)benzoyl]-2-aryl-6-hydroxybenzo[b]thiophenen | |
AT504859B1 (de) | Verfahren zur herstellung von 3-(4-(2-aminoethoxy)benzoyl)-2-aryl-6- hydroxybenzo(b)thiophenen | |
US4380635A (en) | Synthesis of acylated benzothiophenes | |
DE60207406T2 (de) | Heteroaryloxy 3-substituierte propanamine s serotonin und norepinephrin reuptake-inhibitoren | |
EP0062505B1 (de) | Verfahren zur Herstellung von acylierten Benzothiophenen | |
DE60104717T2 (de) | Benzothiophenderivate, verhahren zu ihrer herstellung und ihre verwendung | |
DD201793A5 (de) | Verfahren zur herstellung von 6-hydroxy-2-(4-hydroxy-phenyl) 3-(4-(2-aminoethoxy)benzoyl)benzo(b)thiophenen | |
DD294718A5 (de) | Verfahren zur herstellung von krampfloesenden mitteln | |
DE60223227T2 (de) | BenzoÄbÄthiophenderivate und Verfahren zu deren Herstellung | |
DE3927049A1 (de) | Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung | |
DE69723188T2 (de) | Benzo[B]indeno[2,1-D]thiophenverbindungen, Zwischenprodukte, Verfahren, Zusammensetzungen und Methoden | |
CH691431A5 (de) | Nichtsolvatisierte kristalline Form von Raloxifen als Pharmazeutikum | |
DE60007599T2 (de) | Verfahren zur Herstellung von zyklischen Piperidinylaminomethyl-trifluoromethyl-etherderivaten | |
DD201794A5 (de) | Verfahren zur herstellung von 6-hydroxy-2-(4-hydroxyphenyl) 3-(4-(2-aminoethoxy)benzoyl)benzo(b)thiophenen | |
CH498833A (de) | Verfahren zur Herstellung von neuen Indolderivaten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8110 | Request for examination paragraph 44 | ||
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
R082 | Change of representative |
Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, DE |
|
R082 | Change of representative |
Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, DE |
|
R082 | Change of representative |
Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, DE |
|
R081 | Change of applicant/patentee |
Owner name: DAIICHI SANKYO EUROPE GMBH, DE Free format text: FORMER OWNER: ELI LILLY AND CO., INDIANAPOLIS, IND., US Effective date: 20120903 Owner name: DAIICHI SANKYO EUROPE GMBH, DE Free format text: FORMER OWNER: ELI LILLY AND CO., INDIANAPOLIS, US Effective date: 20120903 |
|
R082 | Change of representative |
Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, DE Effective date: 20120209 Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, DE Effective date: 20120731 Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, DE Effective date: 20120903 |
|
R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |